Updates from DECLARE-TIMI 58: Dapagliflozin offers cardiorenal benefit across the board in patients with T2DM

26 Feb 2020
Diabetes may blunt response to CRT in Asians with HF
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.

Related MIMS Drugs

Editor's Recommendations